Oruka Therapeutics, Inc. ORKA Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s effective income tax rate reconciliation at federal statutory income tax rate, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s effective income tax rate reconciliation at federal statutory income tax rate, amount?
- Oruka Therapeutics, Inc. (ORKA) reported effective income tax rate reconciliation at federal statutory income tax rate, amount of -$5.54M in Q4 2025.
- How has Oruka Therapeutics, Inc.'s effective income tax rate reconciliation at federal statutory income tax rate, amount changed year-over-year?
- Oruka Therapeutics, Inc.'s effective income tax rate reconciliation at federal statutory income tax rate, amount increased by 68.5% year-over-year, from -$17.58M to -$5.54M.
- What does effective income tax rate reconciliation at federal statutory income tax rate, amount mean?
- The theoretical income tax expense or benefit calculated by applying the standard federal statutory tax rate to the company's pre-tax income. This serves as the baseline for the tax reconciliation process, allowing investors to understand the impact of various tax credits and deductions. It highlights the difference between the statutory tax burden and the actual tax expense reported.